In a phase 3 trial (ALTA‐3), median IRC‐assessed PFS was 19.3 months, the ORR was 52%, and the intracranial ORR was 73% with brigatinib given as second‐line treatment to patients with ALK+ NSCLC who had progressed on crizotinib.11 This evidence concerns the gene ALK and non-small cell lung carcinoma.